"Urological Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of urogenital conditions and diseases such as URINARY INCONTINENCE; PROSTATIC HYPERPLASIA; and ERECTILE DYSFUNCTION.
| Descriptor ID |
D064804
|
| MeSH Number(s) |
D27.505.954.944
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Urological Agents".
Below are MeSH descriptors whose meaning is more specific than "Urological Agents".
This graph shows the total number of publications written about "Urological Agents" by people in this website by year, and whether "Urological Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 4 | 2 | 6 |
| 2018 | 4 | 0 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Urological Agents" by people in Profiles.
-
The use of a novel smartphone app for monitoring male luts treatment during the COVID-19 outbreak. Prostate Cancer Prostatic Dis. 2020 12; 23(4):724-726.
-
Deep vein thrombosis associated with sildenafil. Emergencias. 2019 02; 31(1):72.
-
Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. Eur Urol. 2019 01; 75(1):129-168.
-
Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies. Eur Urol. 2018 11; 74(5):633-643.
-
Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. Neurourol Urodyn. 2018 06; 37(5):1693-1700.
-
Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study). BJU Int. 2018 08; 122(2):317-325.
-
Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol. 2018 03; 25(3):196-205.
-
Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone. Sci Rep. 2017 11 09; 7(1):15179.
-
Topical alprostadil (Vitaros©) in the treatment of erectile dysfunction after non-nerve-sparing robot-assisted radical prostatectomy. Urologia. 2018 05; 85(2):55-59.
-
Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol. 2017 Nov; 49(11):2019-2026.